EMAIL THIS PAGE TO A FRIEND

Chest

Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.


PMID 23546483

Abstract

Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been the mainstay of therapy for > 60 years, but both classes of agents have limitations. The "ideal" anticoagulant should be as effective and safe as heparin and vitamin K antagonists but should also be available in both a parenteral and an oral formulation, have predictable pharmacokinetics, and lack significant toxicities unrelated to the anticoagulant activity. Moreover, it should target a specific coagulation factor and have an antidote that leads to rapid reversal. There are now agents that fulfill some of these criteria. Here we review the pharmacology and effectiveness of the oral activated factor X inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran. These agents have undergone extensive phase 3 testing and are currently approved for various indications in the United States, Canada, or Europe. Rivaroxaban is approved in the United States for VTE prevention after major orthopedic surgery and for stroke prevention in atrial fibrillation and is approved in Europe and Canada for secondary prevention of VTE. Apixaban is currently under review by the US Food and Drug Administration for stroke prevention and is approved in Europe for VTE prevention following major orthopedic surgery. Dabigatran is approved in the United States for stroke prevention in nonvalvular atrial fibrillation and is being reviewed for secondary prevention of VTE.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

F9302
Factor X Activated (Xa) from bovine plasma, aqueous glycerol solution
T4648 Thrombin from bovine plasma, lyophilized powder, 40-300 NIH units/mg protein (biuret)
T7513 Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
T6634 Thrombin from bovine plasma, lyophilized powder, 600-2,000 NIH units/mg protein (biuret)
T9549 Thrombin from bovine plasma, powder, cell culture tested, ≥1,500 NIH units/mg protein (E1%/280 = 19.5)
T9000 Thrombin from bovine plasma, buffered aqueous solution, ≥125 NIH units/mg protein (biuret)
T7201 Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
T7326
Thrombin from bovine plasma, ≥60 NIH units/mg protein (biuret)
T7009
Thrombin from human plasma, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)
T1063
Thrombin from human plasma, lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)
T8885
Thrombin from human plasma, lyophilized powder, Suitable for routine use in the thrombin time test
T4393
Thrombin from human plasma, lyophilized powder, 1500-3500 NIH units/mg protein (E1%/280, 18.3), cell culture tested
T7572
Thrombin from human plasma, 400-1000 NIH units/mg protein
T5772 Thrombin from rat plasma, lyophilized powder, ≥1,000 units/mg protein (biuret)
T9326 Thrombin human, BioUltra, recombinant, expressed in HEK 293 cells, aqueous solution, ≥95% (SDS-PAGE)